Bispecific molecules for use in inducing antibody dependent effector cell-mediated cytotoxicity
US5833985A · kind A · utility
48Cited by
3References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 26, 1995 |
| Grant date | Nov 10, 1998 |
| Priority date | — |
| Expiry date | May 26, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Bispecific molecules comprising a non-immunoglobulin tumor cell specific ligand and an antibody which binds the Fc receptor of an effector cell at a site that is not inhibited by endogenous immunoglobulin are disclosed. The bispecific molecules can be used to induce a specific antibody dependent effector cell-mediated cytotoxicity against tumor cells, such as small cell lung carcinoma (SCLC) cells, either in vivo or in vitro.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.